{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:57:05Z","timestamp":1790733425185,"version":"4.1.0"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adoption of high-throughput, gene panel-based, next-generation sequencing (NGS) into routine cancer care is widely supported, but hampered by concerns about cost. To inform policies regarding genomic testing strategies, we propose a simple metric, cost per correctly identified patient (CCIP), that compares sequential single-gene testing (SGT) vs. multiplex NGS in different tumor types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A genomic testing cost calculator was developed based on clinically actionable genomic alterations identified in the European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets. Using sensitivity\/specificity data for SGTs (immunohistochemistry, polymerase chain reaction, and fluorescence in situ hybridization) and NGS and marker prevalence, the number needed to predict metric was monetarized to estimate CCIP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At base case, CCIP was lower with NGS than sequential SGT for advanced\/metastatic non-squamous non-small cell lung cancer (NSCLC), breast, colorectal, gastric cancers, and cholangiocarcinoma. CCIP with NGS was also favorable for squamous NSCLC, pancreatic, and hepatic cancers, but with overlapping confidence intervals. CCIP favored SGT for prostate cancer. Alternate scenarios using different price estimates for each test showed similar trends, but with incremental changes in the magnitude of difference between NGS and SGT, depending on price estimates for each test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The cost to correctly identify clinically actionable genomic alterations was lower for NGS than sequential SGT in most cancer types evaluated. Decreasing price estimates for NGS and the rapid expansion of targeted therapies and accompanying biomarkers are anticipated to further support NGS as a preferred diagnostic standard for precision oncology.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyad005","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T15:36:10Z","timestamp":1679672170000},"page":"e242-e253","source":"Crossref","is-referenced-by-count":22,"title":["Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator"],"prefix":"10.1093","volume":"28","author":[{"given":"Albrecht","family":"Stenzinger","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cuffel","sequence":"additional","affiliation":[{"name":"Bayer Pharmaceuticals , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[{"name":"Bayer Pharmaceuticals , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vail","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Garcia-Foncillas","sequence":"additional","affiliation":[{"name":"University Cancer Institute and the Department of Oncology, University Hospital Fundacion Jimenez Diaz , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Goodman","sequence":"additional","affiliation":[{"name":"The Lewin Group, Inc. , Falls Church, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Lassen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[{"name":"Gustave Roussy Comprehensive Cancer Center, Villejuif , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D","family":"Sullivan","sequence":"additional","affiliation":[{"name":"CHOICE Institute, Department of Pharmacy, School of Pharmacy, University of Washington , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"issue":"3","key":"2023080410423339600_CIT0001","doi-asserted-by":"crossref","first-page":"1735910","DOI":"10.1080\/23723556.2020.1735910","article-title":"Complexities of pharmacogenomic interactions in cancer","volume":"7","author":"Khanna","year":"2020","journal-title":"Mol Cell Oncol."},{"issue":"7","key":"2023080410423339600_CIT0002","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","article-title":"JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol."},{"issue":"6","key":"2023080410423339600_CIT0003","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-020-00915-5","article-title":"Tumor-agnostic treatment for cancer: when how is better than where.","volume":"40","author":"Lavacchi","year":"2020","journal-title":"Clin Drug Invest."},{"issue":"8","key":"2023080410423339600_CIT0004","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2023080410423339600_CIT0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-017-2268-y","article-title":"Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study","volume":"472","author":"Schwegler","year":"2018","journal-title":"Virchows Arch."},{"issue":"4","key":"2023080410423339600_CIT0006","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol."},{"issue":"19","key":"2023080410423339600_CIT0007","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA."},{"issue":"3","key":"2023080410423339600_CIT0008","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s12325-020-01617-2","article-title":"Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced Non-Small Cell Lung Cancer (aNSCLC) using real-world electronic health record data","volume":"38","author":"John","year":"2021","journal-title":"Adv Ther."},{"key":"2023080410423339600_CIT0009","author":"European Society for Medical Oncology"},{"issue":"11","key":"2023080410423339600_CIT0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023080410423339600_CIT0011","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mgg3.201","article-title":"Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.","volume":"4","author":"Xie","year":"2016","journal-title":"Mol Genet Genom Med."},{"issue":"2","key":"2023080410423339600_CIT0012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/jpm5020165","article-title":"Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies","volume":"5","author":"Hillman","year":"2015","journal-title":"J Pers Med."},{"key":"2023080410423339600_CIT0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12907-015-0020-6","article-title":"Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer","volume":"15","author":"Arsenic","year":"2015","journal-title":"BMC Clin Pathol."},{"issue":"10","key":"2023080410423339600_CIT0014","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"25","key":"2023080410423339600_CIT0015","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2023080410423339600_CIT0016","first-page":"35","article-title":"Clinical utility of next-generation sequencing in precision oncology.","volume":"32","author":"Hux","year":"2019","journal-title":"J Am Acad Phys Assist."},{"issue":"5","key":"2023080410423339600_CIT0017","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J Clin Invest."},{"issue":"33","key":"2023080410423339600_CIT0018","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol."},{"issue":"11","key":"2023080410423339600_CIT0019","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol."},{"issue":"1","key":"2023080410423339600_CIT0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/jpm12010072","article-title":"Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe","volume":"12","author":"Horgan","year":"2022","journal-title":"J Pers Med."},{"key":"2023080410423339600_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model","volume":"3","author":"Pennell","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"2023080410423339600_CIT0022","first-page":"285","article-title":"Next-generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach?","volume":"5","author":"Pruneri","year":"2021","journal-title":"PharmacoEcon."},{"key":"2023080410423339600_CIT0023","doi-asserted-by":"crossref","first-page":"e2100349","DOI":"10.1200\/PO.21.00349","article-title":"Clinical utility of genomic testing in cancer care","volume":"6","author":"Pritchard","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"2023080410423339600_CIT0024","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.20.01572","article-title":"Defining clinical utility of tumor biomarker tests: a clinician\u2019s viewpoint","volume":"39","author":"Hayes","year":"2021","journal-title":"J Clin Oncol."},{"key":"2023080410423339600_CIT0025","doi-asserted-by":"crossref","first-page":"1758835920975613","DOI":"10.1177\/1758835920975613","article-title":"A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors","volume":"12","author":"Forsythe","year":"2020","journal-title":"Ther Adv Med Oncol."},{"key":"2023080410423339600_CIT0026","first-page":"PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types.","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"2023080410423339600_CIT0027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2021.08.002","article-title":"Cancer Biomarkers in the era of precision oncology: addressing the needs of patients and health systems","volume":"84","author":"Normanno","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"4","key":"2023080410423339600_CIT0028","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","article-title":"DNA-based versus RNA-based detection of MET Exon 14 skipping events in lung cancer","volume":"14","author":"Davies","year":"2019","journal-title":"J Thorac Oncol."},{"issue":"2","key":"2023080410423339600_CIT0029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.soc.2007.12.001","article-title":"Genomics and proteomics in predicting cancer outcomes.","volume":"17","author":"Parikh","year":"2008","journal-title":"Surg Oncol Clin N Am."},{"key":"2023080410423339600_CIT0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-5573-3-11","article-title":"New patient-oriented summary measure of net total gain in certainty for dichotomous diagnostic tests","volume":"3","author":"Linn","year":"2006","journal-title":"Epidemiol Perspect Innov."},{"issue":"3","key":"2023080410423339600_CIT0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000492783","article-title":"Number needed to diagnose, predict, or misdiagnose: useful metrics for non-canonical signs of cognitive status?","volume":"8","author":"Larner","year":"2018","journal-title":"Dement Geriatr Cogn Dis Extra."},{"issue":"1","key":"2023080410423339600_CIT0032","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4997\/jrcpe.2018.104","article-title":"ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing","volume":"48","author":"Kheng","year":"2018","journal-title":"J R Coll Physicians Edinb."},{"issue":"1","key":"2023080410423339600_CIT0033","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol."},{"issue":"20","key":"2023080410423339600_CIT0034","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2023080410423339600_CIT0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAT.0b013e3283513e8b","article-title":"Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas","volume":"44","author":"Cho","year":"2012","journal-title":"Pathology."},{"issue":"3","key":"2023080410423339600_CIT0036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jso.21220","article-title":"Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype","volume":"99","author":"Seo","year":"2009","journal-title":"J Surg Oncol."},{"issue":"14","key":"2023080410423339600_CIT0037","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/sj.onc.1207361","article-title":"Identification and validation of an ERBB2 gene expression signature in breast cancers","volume":"23","author":"Bertucci","year":"2004","journal-title":"Oncogene."},{"issue":"4","key":"2023080410423339600_CIT0038","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2559.2003.01598.x","article-title":"Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study","volume":"42","author":"Vincent-Salomon","year":"2003","journal-title":"Histopathology."},{"issue":"4","key":"2023080410423339600_CIT0039","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00129039-200112000-00011","article-title":"A reliable method of demonstrating HER-2\/neu, estrogen receptors, and progesterone receptors on routinely processed cytologic material","volume":"9","author":"McKee","year":"2001","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"1","key":"2023080410423339600_CIT0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jcp.2006.043562","article-title":"Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy","volume":"61","author":"Hofmann","year":"2008","journal-title":"J Clin Pathol."},{"issue":"10","key":"2023080410423339600_CIT0041","first-page":"704","article-title":"[Value of detection of DNA mismatch repair proteins deficiency by immunohistochemistry in predicting tumor microsatellite status].","volume":"44","author":"Qin","year":"2015","journal-title":"Chin J Pathol."},{"issue":"1","key":"2023080410423339600_CIT0042","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1186\/s12885-018-5127-6","article-title":"Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study","volume":"18","author":"Jang","year":"2018","journal-title":"BMC Cancer."},{"issue":"11","key":"2023080410423339600_CIT0043","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol."},{"issue":"5","key":"2023080410423339600_CIT0044","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00428-016-1904-2","article-title":"In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading","volume":"468","author":"Pican\u00e7o-Albuquerque","year":"2016","journal-title":"Virchows Arch."},{"issue":"5","key":"2023080410423339600_CIT0045","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jtho.2021.01.1619","article-title":"RET fluorescence in situ hybridization analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer","volume":"16","author":"Radonic","year":"2021","journal-title":"J Thorac Oncol."},{"issue":"5","key":"2023080410423339600_CIT0046","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41374-021-00536-2","article-title":"An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology","volume":"101","author":"Piton","year":"2021","journal-title":"Lab Invest."},{"issue":"14","key":"2023080410423339600_CIT0047","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023080410423339600_CIT0048","doi-asserted-by":"crossref","first-page":"e0117032","DOI":"10.1371\/journal.pone.0117032","article-title":"Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One."},{"issue":"8","key":"2023080410423339600_CIT0049","doi-asserted-by":"crossref","first-page":"e70839","DOI":"10.1371\/journal.pone.0070839","article-title":"Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"2023080410423339600_CIT0050","doi-asserted-by":"crossref","first-page":"16943","DOI":"10.1038\/s41598-020-72809-7","article-title":"A highly sensitive and specific real-time quantitative PCR for BRAF V600E\/K mutation screening","volume":"10","author":"Lung","year":"2020","journal-title":"Sci Rep."},{"issue":"3","key":"2023080410423339600_CIT0051","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3892\/or.2013.2229","article-title":"Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria","volume":"29","author":"Harl\u00e9","year":"2013","journal-title":"Oncol Rep."},{"issue":"8","key":"2023080410423339600_CIT0052","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1373\/clinchem.2019.302315","article-title":"Breast cancer subtype classification using 4-Plex droplet digital PCR","volume":"65","author":"Chen","year":"2019","journal-title":"Clin Chem."},{"issue":"5","key":"2023080410423339600_CIT0053","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/jclinpath-2015-203345","article-title":"Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study","volume":"69","author":"Colling","year":"2016","journal-title":"J Clin Pathol."},{"issue":"7","key":"2023080410423339600_CIT0054","doi-asserted-by":"crossref","first-page":"e0219204","DOI":"10.1371\/journal.pone.0219204","article-title":"Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation","volume":"14","author":"Gilson","year":"2019","journal-title":"PLoS One."},{"key":"2023080410423339600_CIT0055","doi-asserted-by":"crossref","first-page":"101745","DOI":"10.1016\/j.mcp.2021.101745","article-title":"Digital PCR detection of EGFR somatic mutations in non-small-cell lung cancer formalin fixed paraffin embedded samples","volume":"58","author":"Carvalho","year":"2021","journal-title":"Mol Cell Probes."},{"issue":"2","key":"2023080410423339600_CIT0056","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00428-018-2486-y","article-title":"Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma","volume":"474","author":"Colling","year":"2019","journal-title":"Virchows Arch."},{"key":"2023080410423339600_CIT0057","doi-asserted-by":"crossref","first-page":"1385087","DOI":"10.1155\/2013\/385087","article-title":"Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology","volume":"2013","author":"Roma","year":"2013","journal-title":"Biomed Res Int."},{"issue":"8","key":"2023080410423339600_CIT0058","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1089\/gtmb.2015.0069","article-title":"Nonenriched PCR versus mutant-enriched PCR in detecting selected epidermal growth factor receptor gene mutations among nonsmall-cell lung cancer patients","volume":"19","author":"Zaki","year":"2015","journal-title":"Genet Test Mol Biomarkers."},{"issue":"61","key":"2023080410423339600_CIT0059","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.18632\/oncotarget.21476","article-title":"Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer","volume":"8","author":"Ilie","year":"2017","journal-title":"Oncotarget."},{"issue":"4","key":"2023080410423339600_CIT0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1309\/AJCP40XETVYAMJPY","article-title":"Comparison of next-generation sequencing and mutation-specific platforms in clinical practice","volume":"143","author":"Hinrichs","year":"2015","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"2023080410423339600_CIT0061","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.cllc.2018.10.004","article-title":"Molecular diagnostic assays and clinicopathologic implications of MET Exon 14 skipping mutation in non-small-cell lung cancer","volume":"20","author":"Kim","year":"2019","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"2023080410423339600_CIT0062","doi-asserted-by":"crossref","first-page":"e0171225","DOI":"10.1371\/journal.pone.0171225","article-title":"Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method","volume":"12","author":"Takase","year":"2017","journal-title":"PLoS One."},{"issue":"4","key":"2023080410423339600_CIT0063","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/gcc.22431","article-title":"Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance","volume":"56","author":"Pfarr","year":"2017","journal-title":"Genes Chromosom Cancer."},{"issue":"2","key":"2023080410423339600_CIT0064","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J Mol Diagn."},{"key":"2023080410423339600_CIT0065","doi-asserted-by":"crossref","first-page":"720727","DOI":"10.3389\/fonc.2021.720727","article-title":"Circulating cell-free DNA-based detection of suppressor gene copy number loss and its clinical implication in metastatic prostate cancer","volume":"11","author":"Dong","year":"2021","journal-title":"Front Oncol."},{"issue":"4","key":"2023080410423339600_CIT0066","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12253-020-00844-w","article-title":"Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers","volume":"26","author":"Niu","year":"2020","journal-title":"Pathol Oncol Res."},{"issue":"1","key":"2023080410423339600_CIT0067","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-018-0341-y","article-title":"Microsatellite instability in prostate cancer by PCR or next-generation sequencing","volume":"6","author":"Hempelmann","year":"2018","journal-title":"J ImmunoTher Cancer."},{"issue":"2","key":"2023080410423339600_CIT0068","first-page":"2191","article-title":"Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer","volume":"18","author":"Jing","year":"2018","journal-title":"Mol Med Rep."},{"issue":"1","key":"2023080410423339600_CIT0069","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4143\/crt.2021.218","article-title":"Comparison of the data of a next-generation sequencing panel from K-MASTER project with that of orthogonal methods for detecting targetable genetic alterations","volume":"54","author":"Choi","year":"2022","journal-title":"Cancer Res Treat."},{"issue":"4","key":"2023080410423339600_CIT0070","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.prp.2018.02.001","article-title":"Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study","volume":"214","author":"Velizheva","year":"2018","journal-title":"Pathol Res Pract."},{"issue":"12","key":"2023080410423339600_CIT0071","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med."},{"issue":"1","key":"2023080410423339600_CIT0072","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12967-020-02373-1","article-title":"A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients","volume":"18","author":"Zheng","year":"2020","journal-title":"J Transl Med."},{"issue":"5","key":"2023080410423339600_CIT0073","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/00365513.2016.1183813","article-title":"Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing","volume":"76","author":"Xu","year":"2016","journal-title":"Scand J Clin Lab Invest."},{"issue":"1","key":"2023080410423339600_CIT0074","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5858\/arpa.2018-0441-OA","article-title":"Validation of a next-generation sequencing assay targeting RNA for the multiplexed detection of fusion transcripts and oncogenic isoforms","volume":"144","author":"Sussman","year":"2020","journal-title":"Arch Pathol Lab Med."},{"issue":"3","key":"2023080410423339600_CIT0075","doi-asserted-by":"crossref","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One."},{"issue":"2","key":"2023080410423339600_CIT0076","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial","volume":"19","author":"Lih","year":"2017","journal-title":"J Mol Diagn."},{"issue":"1","key":"2023080410423339600_CIT0077","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jmoldx.2013.10.002","article-title":"Validation of a next-generation sequencing assay for clinical molecular oncology","volume":"16","author":"Cottrell","year":"2014","journal-title":"J Mol Diagn."},{"issue":"24","key":"2023080410423339600_CIT0078","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget."},{"issue":"18","key":"2023080410423339600_CIT0079","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2014.59.3665","article-title":"Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis","volume":"33","author":"Gallego","year":"2015","journal-title":"J Clin Oncol."},{"issue":"7","key":"2023080410423339600_CIT0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/gim.2014.156","article-title":"The cost-effectiveness of returning incidental findings from next-generation genomic sequencing","volume":"17","author":"Bennette","year":"2015","journal-title":"Genet Med."},{"issue":"4","key":"2023080410423339600_CIT0081","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2017.01.006","article-title":"A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer.","volume":"20","author":"Li","year":"2017","journal-title":"Value Heal."},{"issue":"1","key":"2023080410423339600_CIT0082","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12885-020-07240-2","article-title":"Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients","volume":"20","author":"Schluckebier","year":"2020","journal-title":"BMC Cancer."},{"key":"2023080410423339600_CIT0083","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer."},{"key":"2023080410423339600_CIT0084"},{"key":"2023080410423339600_CIT0085","author":"Anticancer Fund","year":"2022"},{"issue":"4","key":"2023080410423339600_CIT0086","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med."},{"key":"2023080410423339600_CIT0087","author":"US Food & Drug Administration"},{"key":"2023080410423339600_CIT0088","author":"European Medicines Agency"},{"key":"2023080410423339600_CIT0089","author":"Informa Business Intelligence","year":"2022"},{"key":"2023080410423339600_CIT0090","author":"U.S. Food & Drug Administration"},{"issue":"4","key":"2023080410423339600_CIT0091","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell."},{"issue":"10","key":"2023080410423339600_CIT0092","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","article-title":"Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy","volume":"15","author":"Cabel","year":"2018","journal-title":"Nat Rev Clin Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/e242\/51037275\/oyad005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/e242\/51037275\/oyad005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T09:06:36Z","timestamp":1701680796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/e242\/7085632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":92,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,24]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad005","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,24]]}}}